Mental Health 2019 - Partner Profile - Lundbeck
Date of preparation: July 2019
Job number: UK-NOTPR-0087
Lundbeck Ltd. have provided financial support for venue hire, catering, and exhibition space. They have had no influence over the content or organisation of the meeting, aside from the sponsored Headline Partner session marked in the programme.
Who are Lundbeck?
Lundbeck is a fully-integrated neuroscience pharmaceutical company, which means that we develop new treatments from the point of discovering a promising new molecule, all the way through the development process to regulatory approval, manufacture and distribution.
Brain diseases are the leading cause of disability worldwide and account for 37% of healthy life years lost from non-communicable diseases, representing an alarmingly high and increasing burden for society [Ref.1]. A study by the World Economic Forum estimates that the total global cost of mental illness is expected to increase to 6 trillion USD in 2030, more than double the total cost of cancer, diabetes and cardiovascular diseases combined [Ref.2].Despite the vast unmet needs within psychological and neurological disorders, investment in the research of new treatments has fallen significantly in recent years [Ref.3], however Lundbeck remains committed and our research and development is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of brain diseases. We are specialists in our area and have a research facility in Denmark, reinvesting around 20% of our revenue into R&D. We cooperate closely with strategic partners all over the world, ensuring a good foundation for innovation and the development of new treatment solutions.
How has Lundbeck improved people’s mental health in the UK?
Lundbeck has discovered, developed, manufactured and distributed several medications used every day in the UK to treat people living with depression, schizophrenia, Alzheimer’s Disease or Parkinson’s Disease. The medicines developed by Lundbeck are currently used by over 65,000 patients living with psychological and neurological disorders in the UK.Lundbeck also invests in developing tools and resources that can support the NHS and social care organisations deliver improved patient outcomes and benefit population health, including the Impact of Depression Resource and Impact of Schizophrenia Resource. These tools have been developed as a service to the NHS and bring together a range of NHS Digital data sets that allow NHS organisations to see activity levels, costs and resource utilisation across the health economy, helping to inform commissioning decisions, support NICE implementation and improve pathways of care.
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
Every medication Lundbeck successfully develops to a stage where it is licensed and available for patients is a huge achievement – it can take up to 15 years and cost in excess of £4 billion [Ref.4]. Each medicine successfully developed provides doctors with another treatment option for their patients, and every day our medicines help patients all over the world living with brain diseases.
How many organisations/clients currently utilise the service/solution across the UK?
Lundbeck works with NHS organisations across the UK to help support local NHS objectives and improvements in the care and management of patients suffering from brain disease. We are always open to working in partnership to improve the lives of patients.
Is there anything you would like to make delegates aware of ahead of the Mental Health 2019 conference on 26th September?
Lundbeck is committed to supporting the NHS and social care organisations to improve the lives of patients suffering from psychological and neurological conditions, not only through our investment in the research and development of new medicines, but also through partnership working with organisations to support NICE implementation and improvements in pathways of care.
Our main areas of focus currently are depression and schizophrenia and we have a range of tools and resources available to support NICE implementation. Lundbeck is always open to discussions on ways we can support local NHS objectives and improvements in the care and management of patients suffering from psychological and neurological conditions.
What do you feel are the key points delegates need to digest when considering a partnership with Lundbeck?
Lundbeck’s focus on mental health has led us to be an organisation that understands healthcare systems and service models well beyond just the pharmacological aspects of healthcare. This enables us to support a holistic, whole pathway approach to improving the care of patients, helping the NHS improve patient outcomes and identify potential efficiencies across the health economy.
Whilst Lundbeck is a commercial organisation, the Lundbeck Foundation owns 70% of the shares and annually distributes around 500m DKK (£60m [Ref.5]) in research grants each year, with the remaining 30% of shares being traded on the stock exchange [Ref.6].
Lundbeck reinvests significant revenue each year into the research & development of new treatments so that we can continue to improve the lives of patients in the future.
1. World Health Organization. (WHO 2008). The Global Burden of Disease: 2004 Update.
2. Bloom, D.E., Cafiero, E.T., Jané-Llopis, E., Abrahams-Gessel, S., Bloom, L.R., Fathima, S., Feigl, A.B., Gaziano, T., Mowafi, M., Pandya, A., Prettner, K., Rosenberg, L., Seligman, B., Stein, A.Z., & Weinstein, C. (2011). The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum.
3. ECNP Summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin. European Neuropsychopharmacology (2011) 21, 495–499.
4. Marston H. A Brief History of Psychiatric Drug Development. British Association for Psychopharmacology. April 2013. Available at: https://www.bap.org.uk/articles/a-brief-history-of-psychiatric-drug-development/ (Accessed: July 2019).
5. 1 GBP = 8.3211 DKK, 1st July 2019.
6. https://www.lundbeck.com/global/about-us/facts-and-background (Accessed July 2019)